Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Effects of PN2034 in Insulin-Dependent Patients With Type 2 Diabetes
This study is designed to evaluate the safety and efficacy of PN2034 in insulin-dependent type 2 diabetics as measured by the change in average daily insulin dose from baseline to week 12. The effects of PN2034 on HbA1c, fasting plasma glucose (FPG), and lipid levels will also be measured.
Age
21 - 65 years
Sex
ALL
Healthy Volunteers
No
Phoenix Internal Medicine Associates
Waterbury, Connecticut, United States
Center for Diabetes and Endocrine Care
Hollywood, Florida, United States
Genesis Research International
Longwood, Florida, United States
Baptist Diabetes Associates
Miami, Florida, United States
Andres Patron, DO PA
Pembroke Pines, Florida, United States
CLIRECO,Inc.
Tamarac, Florida, United States
Endocrine Clinical Research
Winter Park, Florida, United States
PRN of Kansas
Wichita, Kansas, United States
Medical Research Associates of Charlotte
Charlotte, North Carolina, United States
Neem Research Group of Charlotte
Charlotte, North Carolina, United States
Start Date
May 1, 2005
Completion Date
April 1, 2007
Last Updated
August 23, 2007
90
ESTIMATED participants
PN2034
DRUG
Insulin
DRUG
Lead Sponsor
Wellstat Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07433062